Study on the Underlying Mechanism of Yinhua Gout Granules in the Treatment of Gouty Arthritis by Integrating Transcriptomics and Network Pharmacology
Qiang-qiang Fan,Bing-tao Zhai,Dan Zhang,Xiao-fei Zhang,Jiang-xue Cheng,Dong-yan Guo,Huan Tian
DOI: https://doi.org/10.2147/dddt.s475442
IF: 4.3188
2024-07-19
Drug Design Development and Therapy
Abstract:Qiang-qiang Fan, 1 Bing-tao Zhai, 1 Dan Zhang, 1 Xiao-fei Zhang, 1 Jiang-xue Cheng, 1 Dong-yan Guo, 1– 3 Huan Tian 4 1 School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, 712046, People's Republic of China; 2 Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xi'an, 712046, People's Republic of China; 3 State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), Shaanxi University of Chinese Medicine, Xi'an, 712046, People's Republic of China; 4 Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 712046, People's Republic of China Correspondence: Dong-yan Guo; Huan Tian, Email ; Purpose: Yinhua Gout Granules (YGG) is a traditional Chinese medicine preparation with a variety of pharmacological effects, and its clinical efficacy in the treatment of gouty arthritis (GA) has been fully confirmed. However, the pharmacodynamic basis of YGG and its anti-inflammatory mechanism of action in GA are unknown. The objective of this study was to identify the active components and molecular mechanisms of YGG in the treatment of GA. Methods: Ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) and network pharmacology were used to identify and predict the potential active ingredients and related signaling pathways. Then, we revealed the anti-GA effects of YGG based on pharmacodynamic experiments in GA rats. Finally, we integrated transcriptomics and network pharmacology to elucidate the potential mechanism of action and verified the putative mechanism by molecular docking, immunohistochemical (IHC) and Western blot. Results: We have identified 10 major active components of YGG that may have anti-GA effects, such as ferulic acid, rutin, luteolin, etc. Using molecular docking, we found that 10 major compounds could bind well to TNF, PTGS2, IL-6, IL1β, NOS2 and PTGS1, and the binding energies were all less than − 5 kcal/mol. Animal studies have shown that YGG can improve joint inflammation and inflammatory cell infiltration, reduce serum UA, BUN and Cr levels ( p< 0.01), and decrease IL-1β, IL-6, TNF-α, COX-2 and PGE2 levels in synovial tissue ( p< 0.01), which are associated with the pathogenesis of GA. IHC and Western blot results showed that YGG could regulate TLR4/MYD88/NF-κB pathway to inhibit the inflammatory response induced by GA. Conclusion: This study found that YGG could not only improve the disease of GA by inhibiting the production of UA in the body, but also target the regulation of TLR4/MYD88/NF-κB signaling pathway through a variety of active components to achieve effective therapeutic effects on GA. Keywords: gouty arthritis, Yinhua Gout granules, transcriptomics, TLR4/MYD88/NF-κB signaling pathway Gouty arthritis (GA) is a common metabolic disease in humans caused by abnormalities in purine metabolism and excessive Uric acid (UA) production. 1 Hyperuricemia (HUA) is the basis for the occurrence and development of GA. During the HUA stage, the UA level continues to increase, leading to the deposition of Uric Acid Sodium (MSU) crystals in and around the joints, and then stimulating the body to produce a large number of pro-inflammatory factors, such as Interleukin-1β (IL-1β), Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), etc. Eventually induces GA, accompanied by severe pain and acute inflammation. 2 GA occurs in approximately 1–4% of the general population, and in a few countries, the prevalence is as high as 10%, affecting mainly middle-aged and elderly people and significantly more men than women. 3 In addition, the global incidence of GA is on the rise due to improper dietary habits, inadequate exercise and disorders of metabolism. 4 Currently, effective treatments for GA include reducing inflammation, lowering UA levels in blood and urine, and dissolving MSU crystals to improve arthritis function. Therefore, in the clinical treatment of GA in western medicine, most of them use combination therapy. On the one hand, drugs such as allopurinol tablets, febuxostat tablets, probenecid tablets, and benzbromarone are used to reduce the production of UA or increase the metabolism of UA in patients. 5 On the other hand, the use of colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and painkillers to inhibit articular inflammation in patients with development and ease the pain. 6 However, long-term use of these drugs may cause adverse reactions such as leukopenia, skin and mucous membrane damage, bone marrow suppression, gas -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal